Chemfab Alkalis Ltd Q1 FY27 Results

Chemfab Alkalis' consolidated revenue fell to Rs.73.16 Cr, down 20.1% YoY and 2.2% QoQ, while reported PAT of Rs.5.73 Cr looks like a strong +124.9% YoY jump. That headline is misleading: a Rs.3.80 Cr one-off deferred-tax credit (Note 4) - booked after the company re-measured its opening deferred tax liability following an election of the concessional tax rate under the new Income Tax Act 2025 - drove most of the gain. Stripping it out, adjusted PAT is roughly Rs.1.93 Cr, down about 24% YoY, which tracks a near-53% YoY drop in profit before tax (Rs.2.22 Cr vs Rs.4.70 Cr) far better than the reported PAT figure does.

The revenue and PBT declines are a segment-mix story. Chemicals & Related Products revenue grew 27.6% YoY (Rs.67.41 Cr vs Rs.52.84 Cr) and the segment swung to a Rs.2.92 Cr profit from a Rs.3.72 Cr loss a year ago, but PVC-O Pipes revenue collapsed 85.1% YoY (Rs.5.75 Cr vs Rs.38.70 Cr) and its result flipped from an Rs.8.63 Cr profit to a Rs.0.57 Cr loss, dragging the consolidated top line down even as the core chemicals business improved. Operating profitability actually expanded - EBITDA margin rose to 13.84% from 12.34% YoY and 11.39% QoQ on the richer chemicals mix - but finance cost (+40.7% YoY to Rs.2.21 Cr) and depreciation (+21.7% YoY to Rs.7.78 Cr), tied partly to Rs.14.91 Cr invested this quarter under a hybrid power-purchase agreement, ate into that gain before tax.

The stock went into the print at ₹384.8, down 2.2% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters.

There is no consensus estimate or formal management guidance on record for this micro-cap - a web search turned up no Q1 FY27 preview or brokerage estimates, and our records hold no prior concall or outlook - so vs-street and vs-guidance cannot be assessed beyond 'unknown'. Standalone (parent-only) results show the same tax-credit effect with a much thinner underlying base: PBT of just Rs.1.30 Cr and PAT of Rs.4.83 Cr, indicating the subsidiaries (Chemfab Karaikal, Chemfab Hiitech Piping) supply most of the incremental consolidated profit. Separately, the board approved MSKA & Associates as incoming statutory auditor for a five-year term succeeding Deloitte Haskins & Sells, effective from the next AGM - a governance item unrelated to the quarter's numbers.